Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
February 26 2014 - 8:30AM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that
Ron Bentsur, the Company's Chief Executive Officer, will be
presenting at the following upcoming healthcare investor
conferences:
34TH Annual Cowen and Company Health Care Conference
(Boston, MA)
Presentation Date: Monday, March 3rd, 2014 Presentation Time:
2:50 pm ET
26th Annual ROTH Conference (Dana Point,
CA)
Presentation Date: Monday, March 10th, 2014 Presentation Time:
12:00 Noon PT (3:00pm ET)
Live audio webcasts of these presentations will be accessible
within the Investor Relations section of the Company's Website at
http://www.keryx.com/webcasts-presentations. An archived version of
each webcast will be available following the conclusion of the live
presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of pharmaceutical products for
the treatment of renal disease. Keryx is developing ZerenexTM
(ferric citrate coordination complex), an oral, ferric iron-based
compound. Zerenex has completed a U.S.-based Phase 3 clinical
program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with chronic kidney disease on dialysis,
conducted pursuant to a Special Protocol Assessment (SPA) agreement
with the FDA. Keryx's New Drug Application (NDA), submitted to the
FDA in 2013, is currently under review and has an assigned
Prescription Drug User Fee Act (PDUFA) goal date of June 7, 2014.
The Marketing Authorization Application (MAA) filing with the
European Medicines Agency (EMA) is pending. Zerenex has also
completed a Phase 2 study in the U.S. for the management of
elevated serum phosphorus levels and iron deficiency anemia in
patients with Stage 3 to 5 non-dialysis dependent chronic kidney
disease. In addition, Keryx's Japanese partner, Japan Tobacco, Inc.
and Torii Pharmaceutical Co., Ltd., received marketing approval of
ferric citrate in Japan for the treatment of hyperphosphatemia in
patients with chronic kidney disease on January 17, 2014. Keryx is
headquartered in New York City.
CONTACT: KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024